The MAGIC Trial: Clarification Required
I cannot provide treatment recommendations for asthma patients enrolled in "the Magic trial" because the MAGIC trial identified in the evidence is not an asthma study—it is a fall prevention study in older adults 1.
What the MAGIC Trial Actually Studies
The MAGIC trial (as documented in the provided evidence) is a single-blind randomized controlled trial investigating a home-based case management program to reduce fall risk in people aged 60 years and older who have fallen at least twice in the past 12 months 1. This trial has nothing to do with asthma treatment.
If You Are Asking About Asthma Treatment Generally
If your question is actually about general asthma management rather than a specific trial called "MAGIC," I can provide comprehensive treatment recommendations based on the extensive asthma guidelines provided:
Stepwise Asthma Management Approach
For patients with persistent asthma, inhaled corticosteroids (ICS) are the foundation of long-term control therapy, with treatment intensity adjusted based on disease severity and control status 2, 3.
- The stepwise approach involves stepping up therapy if asthma is not well controlled and stepping down if asthma has been well controlled for at least 3 months 2, 3.
- Short-acting beta-agonists (SABAs) should be used as needed for symptom relief, with use >2 days per week indicating inadequate control and need to step up treatment 2.
Acute Exacerbation Management
For acute severe asthma, immediately administer oxygen (40-60%), nebulized salbutamol 5-10 mg (or terbutaline 10 mg), and oral prednisolone 30-60 mg or IV hydrocortisone 200 mg 4, 5.
- Repeat nebulized beta-agonist every 15-30 minutes if not improving 4.
- Add ipratropium 0.5 mg to nebulizer if patient fails to improve after initial treatment 4.
- Measure peak expiratory flow 15-30 minutes after starting treatment 4.
Critical Safety Warnings
- Sedatives are absolutely contraindicated in asthmatic patients as they worsen respiratory depression 4, 3, 6.
- Long-acting beta-agonists (LABAs) must never be used as monotherapy; patients must continue ICS even if symptoms improve 3.
Please Clarify Your Question
If you are referring to a different asthma trial with a similar name, please provide additional details so I can give you accurate, evidence-based recommendations.